Study to investigate safety and tolerability single ascending doses of AZD4017.

Study identifier:D2060C00007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, single-blind, placebo-controlled, single-centre phase I study in healthy Japanese male volunteers to assess the safety, tolerability and pharmacokinetics of AZD4017 after single ascending oral doses

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4017, Placebo

Sex

Male

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Dec 2008

Primary Completion Date: -

Study Completion Date: 01 Apr 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Fukuoka, Japan

Arms	Assigned Interventions
Experimental: 1 AZD4017 in ascending doses (start dose 2mg)	Drug: AZD4017 ascending single doses (start dose 2 mg), oral suspension
Placebo Comparator: 2 Placebo	Drug: Placebo placebo

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1235&filename=CSR-D2060C00007.pdf
Download
CSR-D2060C00007.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Japan Clinical Study

+81-6-6453-8011

Investigators

Principal Investigator

Shunji Matsuki

Kyusyu Clinical Phramacology Research Clinic